Induction of DT-diaphorase by 1,2-dithiole-3-thiones in human tumour and normal cells and effect on anti-tumour activity of bioreductive agents.
DT-diaphorase is a two-electron-reducing enzyme that is an important activator of bioreductive anti-tumour agents, such as mitomycin C (MMC) and EO9, and is inducible by many compounds, including 1,2-dithiole-3-thiones (D3Ts). We showed previously that D3T selectively increased DT-diaphorase activity in mouse lymphoma cells compared with normal mouse marrow cells, and also increased MMC or EO9 cytotoxic activity in the lymphoma cells with only minor effects in the marrow cells. In this study, we found that D3T significantly increased DT-diaphorase activity in 28 of 38 human tumour cell lines representing ten tissue types with no obvious relationships between the tumour type, or the base level of DT-diaphorase activity, and the ability of D3T to increase the enzyme activity. Induction of DT-diaphorase activity in human tumour cell lines by 12 D3T analogues varied markedly with the D3T structure. D3T also increased DT-diaphorase activity in normal human bone marrow and kidney cells but the increases were small in these cells. In addition, D3T increased the level of enzyme activity in normal human lung cells. Pretreatment of human tumour cells with D3T analogues significantly increased the cytotoxic activity of MMC or EO9 in these cells, and the level of enhancement of anti-tumour activity paralleled the level of DT-diaphorase induction. In contrast, D3T did not effect the toxicity of EO9 in normal kidney cells. These results demonstrate that D3T analogues can increase DT-diaphorase activity in a wide variety of human tumour cells and that this effect can enhance the anti-tumour activity of the bioreductive agents MMC and EO9.
Doherty
G P
GP
Manitoba Institute of Cell Biology, Manitoba Cancer Treatment and Research Foundation, Department of Pharmacology, University of Manitoba, Winnipeg, Canada.
Leith
M K
MK
Wang
X
X
Curphey
T J
TJ
Begleiter
A
A
D000970:Antineoplastic Agents / Q000494:pharmacology*; D001388:Aziridines / Q000494:pharmacology; D001853:Bone Marrow / Q000187:drug effects* / Q000201:enzymology; D002470:Cell Survival / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D004338:Drug Combinations; D004790:Enzyme Induction; D006801:Humans; D045563:Indolequinones; D007211:Indoles / Q000494:pharmacology; D007668:Kidney / Q000187:drug effects* / Q000201:enzymology; D008168:Lung / Q000187:drug effects / Q000201:enzymology; D016685:Mitomycin / Q000494:pharmacology; D016660:NAD(P)H Dehydrogenase (Quinone) / Q000096:biosynthesis*; D013871:Thiones / Q000494:pharmacology*; D013876:Thiophenes / Q000494:pharmacology*; D014407:Tumor Cells, Cultured / Q000187:drug effects* / Q000201:enzymology
D000970:Antineoplastic Agents; D001388:Aziridines; D004338:Drug Combinations; D045563:Indolequinones; D007211:Indoles; D013871:Thiones; D013876:Thiophenes; D016685:Mitomycin; D016660:NAD(P)H Dehydrogenase (Quinone); C060817:apaziquone; C049325:1,2-dithiol-3-thione